logo-loader
viewClinigen Group PLC

Clinigen and Bristol-Myers Squibb sign extended partnership agreement in South Africa

Clinigen and Bristol-Myers Squibb sign extended partnership agreement in South Africa

Shaun Chilton, CEO of Clinigen Group PLC (LON:CLIN) tells Proactive that agreement with Bristol-Myers Squibb proves two things.

“One, that pharmaceutical companies, even the biggest ones, are looking to partner in certain parts of the world in terms of commercialising their medicines,“ Shaun Chilton said.

He added: “And also I think it proves that we have built an infrastructure particularly in Africa, using South Africa as a hub, that makes it a very attractive partner to pharmaceutical companies.”

Quick facts: Clinigen Group PLC

Price: 865.5 GBX

AIM:CLIN
Market: AIM
Market Cap: £1.15 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Clinigen Group PLC named herein, including the promotion by the Company of Clinigen Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Clinigen Group reports on 'transformational' year with strong profit growth

Clinigen Group PLC's (LON:CLIN) head of investor relations Matt Parrish caught up with Proactive London's Andrew Scott following the release of the firm's results for the year to June 2019. The firm's gross profit was up 30% at £182.3mln, while revenues were ahead 20% at £456.9mln. Underlying...

on 19/9/19

2 min read